Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Protocol # 21-756

Status

Recruiting

Description

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

Condition

  • Advanced Solid Tumor

Interventions

  • XTX202

Phase

Phase 1/Phase 2

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 only)
  • Incidence of treatment-emergent adverse events (Phase 1 only)
  • Incidence of changes in clinical laboratory values (Phase 1 only)
  • Investigator-assessed objective response rate (ORR) per RECIST 1.1 (Phase 2 only)

Secondary Outcome:

  • Plasma concentrations of XTX202 (total and intact)
  • Maximum observed plasma concentration (Cmax)
  • Time of maximum observed concentration (Tmax)
  • Trough concentrations (Ctrough)
  • Area under the curve (AUC)
  • Half-life (T1/2)
  • Systemic clearance (CL)
  • Volume of distribution (Vd)
  • Antidrug antibody (ADA) occurrence and titer in serum (Phase 1 only)
  • Investigator-assessed objective response rate (ORR) per RECIST 1.1 (Phase 1 only)
  • Duration of response (DOR) (Phase 2 only)
  • Disease control rate (Phase 2 only)
  • Progression-free survival (PFS) (Phase 2 only)
  • Overall survival (OS) (Phase 2 only)
  • Incidence of treatment-emergent adverse events (Phase 2 only)
  • Incidence of changes in clinical laboratory values (Phase 2 only)

Enrollment

120

Study Start Date

January 18, 2022

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

Xilio Development, Inc.

Source

Xilio Development, Inc.

Official title

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors

Clinicaltrials.gov Identifier

NCT05052268

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.